The Patent Prosecution Process: A Practical Guide From Filing to Grant

Patent prosecution is the term used to describe the entire process by which a patent application is examined by a patent office and either granted or rejected — encompassing everything from the initial filing of the application through the back-and-forth correspondence with the examiner, any appeals that may be necessary, and ultimately the issuance of a granted patent. For a life sciences startup managing applications in multiple jurisdictions simultaneously, understanding how prosecution works in each major system — and how those systems differ from one another — is essential for setting realistic expectations, managing costs, making informed strategic decisions, and avoiding the procedural pitfalls that can derail an otherwise strong application. What follows is a practical overview of the prosecution process in the United States, the Patent Cooperation Treaty (PCT) international system, and Europe, with attention to the distinctive features of prosecution in China and Japan that life sciences applicants most frequently encounter.

U.S. Prosecution: Filing, Examination, and the Road to Grant

Prosecution before the USPTO begins with the filing of a patent application — either a provisional application, which secures a priority date but does not itself result in a patent, or a non-provisional application, which initiates the formal examination process. A non-provisional application must include a written description of the invention, one or more claims defining the scope of protection sought, drawings where necessary, and an abstract. Once filed, the application is assigned to an examiner with subject matter expertise in the relevant technology area, and it enters the examination queue — either the standard queue or, if Track One prioritized examination has been requested, the accelerated queue described later in this booklet. The examiner reviews the application against the four patentability requirements — subject matter eligibility under Section 101, novelty under Section 102, non-obviousness under Section 103, and written description and enablement under Section 112 — and searches the prior art for references that might affect patentability. The first substantive communication from the examiner is known as an office action, and it will either allow the claims as filed — a relatively rare outcome on the first action — or reject some or all the claims on specified grounds, citing prior art references and legal bases for each rejection.

Responding to Office Actions and Advancing to Allowance

The applicant’s response to an office action is one of the most consequential steps in the prosecution process, and it deserves careful attention. A response may include arguments explaining why the examiner’s rejections are incorrect, amendments to the claims that narrow or clarify their scope to distinguish the prior art cited, or a combination of both. The prosecution history created by this exchange — every office action, every response, every amendment — becomes a permanent public record that will be used to interpret the scope of the patent if it is ever litigated, a principle known as prosecution history estoppel. This means that arguments made to distinguish prior art during prosecution can later be used to limit the patent’s coverage in infringement proceedings, and claims amendments that narrow the scope of protection to achieve allowance may foreclose the ability to assert the patent against certain accused products. Applicants typically have one non-final office action and one final office action before the prosecution reaches a decision point — after a final rejection, the applicant can appeal to the Patent Trial and Appeal Board, file a Request for Continued Examination to reopen prosecution, or file a continuation application to pursue the claims further. The average number of office action cycles before allowance in life sciences technology areas has historically been three to four rounds, though the complexity of the technology and the breadth of the claims sought will affect this significantly.

Continuation and Divisional Strategy: Keeping the Portfolio Alive

One of the most powerful and distinctive features of U.S. patent prosecution is the continuation application — a mechanism that allows an applicant to file a new application claiming priority to an earlier parent application, pursuing different or additional claims based on the same original disclosure, as long as the parent application remains pending. Continuation applications are the primary tool through which sophisticated life sciences companies build layered patent portfolios that cover multiple aspects of a product from different angles, adapt their claim strategy as a product develops and the competitive landscape evolves, and maintain pending applications that can be shaped in response to competitor activity or market developments. A well-managed continuation strategy can keep a family of applications active for many years after the original filing, providing ongoing opportunities to secure new patents with claims tailored to the commercial reality of the product as it matures. Divisional applications — a related mechanism triggered when the USPTO determines that a single application contains claims to more than one distinct invention and requires the applicant to elect one for examination — also play an important role in portfolio building, allowing the non-elected inventions to be pursued in separate applications without loss of priority. For life sciences startups, developing a deliberate continuation strategy — planned in advance and executed systematically rather than reactively — is one of the highest-value activities in IP portfolio management.

The PCT Process: International Filing Through a Single Gateway

The PCT system, administered by the World Intellectual Property Organization, provides a unified mechanism for filing patent applications in over 150 member countries through a single international application. Filing a PCT application does not itself result in a granted patent — national or regional patent offices retain the authority to grant patents in their respective jurisdictions — but it provides two enormously valuable benefits: it establishes a single international priority date that is recognized across all PCT member states, and it delays the need to commit to specific national or regional filings — and the significant translation and national phase costs associated with them — for up to 30 months from the earliest priority date. For a life sciences startup that has filed a U.S. provisional application and needs to decide within 12 months whether and where to pursue international protection, filing a PCT application is almost always the right intermediate step, because it preserves the full range of international options while deferring the most significant costs until the commercial picture is clearer.

PCT International Search and Preliminary Examination

Once a PCT application is filed, it is assigned to an International Searching Authority (ISA) — typically the USPTO, the EPO, or another designated national office depending on where the application was filed and the applicant’s preference — which conducts a search of the prior art and issues an International Search Report together with a Written Opinion on the patentability of the claims. The International Search Report identifies prior art documents relevant to novelty and inventive step, while the Written Opinion provides the ISA’s preliminary assessment of whether the claims satisfy the patentability requirements. Although neither the search report nor the written opinion is binding on the national offices that will later examine the application in their respective jurisdictions, they provide valuable early intelligence about the strength of the application and the prior art landscape, and they give the applicant an opportunity to amend the claims before entering national phase. Applicants who wish to receive a more detailed preliminary examination of their amended claims can request an International Preliminary Examining Authority report — a process known as Chapter II examination — which provides a second written opinion on the amended application and can be useful in building a record of patentability arguments that may assist prosecution in multiple national offices simultaneously.

Entering National Phase: From PCT to Individual Jurisdictions

At the end of the PCT international phase, 30 or 31 months from the earliest priority date depending on the jurisdiction, the applicant must enter the national or regional phase in each jurisdiction where protection is sought, filing the necessary translations, paying the required national fees, and complying with any jurisdiction-specific formality requirements. It is at this point that the costs of international patent prosecution escalate significantly, because each national filing requires the engagement of local patent counsel, the preparation of translations where required, and the payment of national filing and examination fees. The decision of which countries to enter at national phase is therefore both a strategic and a financial one, and it should be made with a clear view of the commercial priorities of the business, the expected size of the market in each jurisdiction, the cost of prosecution and maintenance in each country, and the advice of patent counsel familiar with the examination environment in each jurisdiction. Once national phase is entered, prosecution proceeds according to the rules and practices of each individual patent office — meaning that the applicant may face different examination standards, different claim drafting requirements, and different procedural timelines in each country, even if the underlying application is identical.

European Prosecution: Centralized Examination, National Validation

Prosecution before the European Patent Office (EPO) is in many respects the most procedurally distinctive of the major patent systems, and it rewards applicants who understand its specific requirements and prepare accordingly. A European patent application — whether filed directly at the EPO or entering European regional phase from a PCT application — is examined centrally by the EPO under the European Patent Convention, applying the substantive standards discussed earlier in this booklet including the problem-solution approach to inventive step. The EPO examination process begins with a search phase, during which the EPO issues a European Search Report and an accompanying opinion on patentability, followed by a substantive examination phase during which the examiner issues written communications raising objections and the applicant responds with arguments and amendments. One of the most important procedural features of EPO prosecution is the oral proceedings — a formal hearing before the examiner or, in appeal cases, before a Board of Appeal — at which the applicant’s counsel can present arguments in person, and the examiner or board can reach a final decision on allowability. Oral proceedings are commonly used in both European prosecution and in the United States (during examiner interviews), and they can be an effective tool for resolving complex examination issues that are difficult to address adequately through written exchanges alone.

EPO-Specific Considerations for Life Sciences Applicants

Several features of EPO prosecution deserve specific attention from life sciences applicants. The EPO’s prohibition on method of treatment claims, as discussed earlier, requires that therapeutic innovations be claimed in Swiss-style use format or as purpose-limited product claims — a drafting requirement that must be addressed from the outset of the application. The EPO’s strict approach to added subject matter — the prohibition on introducing new information into the claims or description that was not disclosed in the application as originally filed — is among the most stringent of any major patent office, and amendments that would be unremarkable in US prosecution can result in objections or invalidity findings in Europe if they are deemed to extend beyond the original disclosure. The EPO also applies a rigorous approach to sufficiency of disclosure — the European equivalent of the US written description and enablement requirements — that has been particularly challenging for broad claims in the antibody and gene therapy fields, where the EPO has required that the full scope of a claim be enabled across its entire breadth by the examples provided in the application. Once a European patent is granted, it must be validated in individual member states by paying national validation fees and, in some countries, filing translations — a process that adds cost and administrative complexity but that provides nationally enforceable rights in each validated country.

China: Prosecution Practices and Common Challenges

Prosecution before the China National Intellectual Property Administration (CNIPA) has its own distinctive rhythm and set of challenges that life sciences applicants should be prepared for. Chinese examination tends to be highly focused on the specific examples and data provided in the application as filed — examiners will frequently raise objections based on insufficient support for the scope of the claims relative to the working examples, and arguments based on the general knowledge of the skilled person or on post-filing data are given less weight than in US or European prosecution. This means that the quality and completeness of the experimental data included in the original filing is particularly important for Chinese prosecution, and applications that rely heavily on prophetic examples or that claim broad classes of compounds or biologics without comprehensive working examples across the claimed scope are likely to face significant objection. Chinese prosecution also involves a formal two-stage examination process — a preliminary examination that reviews formality requirements followed by substantive examination — and the timelines between office actions can be less predictable than in the United States or Europe, requiring active monitoring and docket management by patent counsel. One practical consideration that is specific to China is the requirement that any invention completed in China be filed first in China — or receive clearance from CNIPA for foreign filing — before being filed abroad, a requirement that has important implications for startups with research activities in China and that must be addressed proactively to avoid inadvertent violations.

China: Claim Drafting and Strategic Considerations

Claim drafting for Chinese prosecution requires specific attention to the scope and structure of the claims in light of CNIPA’s examination practices. Independent claims in Chinese applications tend to be drafted more narrowly than their US counterparts, reflecting the examiner’s expectation that each claim be supported by specific working examples rather than broader functional language. Dependent claims play an important role in Chinese prosecution as a fallback position — because narrowing to dependent claim scope is frequently required to achieve grant — and a well-constructed dependent claim structure can preserve meaningful protection even after significant narrowing during examination. Chinese patent law also has specific provisions governing the patentability of biological materials, genetic resources, and traditional knowledge that have no direct equivalent in the US or European systems and that may affect the strategy for certain life sciences applications involving these subject matters. The enforcement landscape in China, while significantly improved in recent years as noted earlier in this booklet, also has distinctive features that affect how patent portfolios should be structured for effective enforcement — including the importance of having Chinese language claims that are drafted with domestic enforcement in mind from the outset, rather than being adapted from foreign language originals in ways that may create unintended gaps in coverage.

Japan: Examination Practices and Procedural Requirements

Prosecution before the Japan Patent Office (JPO) combines rigorous substantive examination with procedural requirements that differ from both the US and European systems in ways that require careful management. As noted earlier in this booklet, the JPO applies detailed support and enablement standards that frequently result in objections to broad claims, and the examination culture of the JPO rewards precision and specificity in claim drafting over the broader functional claiming styles that can be successful in the United States. One of the most distinctive procedural features of Japanese prosecution is the interview practice — it is common and often productive to request an examiner interview early in the prosecution process, before receiving a formal office action, in order to understand the examiner’s concerns and to explore potential claim amendments that might address those concerns efficiently. Japanese examiners are generally willing to engage constructively in these interviews, and an experienced Japanese patent attorney who maintains productive relationships with JPO examiners can use the interview process to resolve prosecution issues more efficiently than the formal written exchange alone would permit. Japan also has a unique system of divisional applications that differs from the US practice — in Japan, divisional applications can only be filed within a defined window following a restriction requirement or before certain procedural deadlines, and missing these windows can permanently foreclose the ability to pursue divided subject matter, making careful deadline management an essential part of Japanese prosecution practice.

Japan: Unity of Invention and Other Practical Considerations

The JPO applies a strict unity of invention requirement — similar in concept to the restriction practice at the USPTO but applied with greater frequency and specificity in the life sciences context — that can result in a single application being divided into multiple applications covering different inventive concepts. Managing the resulting family of divisional applications, each with its own prosecution timeline and examination issues, requires organized docket management and proactive communication with Japanese counsel. Japanese prosecution also involves a formal appeal system — the JPO Board of Appeals — that provides an important avenue for challenging examiner rejections that cannot be resolved through amendment and argument alone, and appeal proceedings before the JPO Board can be an effective tool for securing broader claim scope than the examiner was willing to allow. One practical consideration worth highlighting for life sciences startups is that Japanese patents, once granted, are subject to opposition proceedings that allow third parties to challenge the patent within a defined window following grant — a mechanism that has been used by competitors in the pharmaceutical space to challenge valuable life sciences patents, and that argues for drafting claims with an eye toward their defensibility in post-grant proceedings as well as their scope during prosecution.

Comparing the Systems: Key Takeaways for Life Sciences Applicants

Viewed together, the patent prosecution systems of the United States, Europe, China, and Japan present a landscape of significant diversity that requires a coordinated and jurisdiction-aware approach to manage effectively. The United States offers the broadest range of claim types, the most flexible prosecution practice, and the most powerful continuation strategy tools, but its Section 101 jurisprudence creates unique challenges for diagnostics and certain biotechnology innovations. Europe provides a unified examination process with rigorous inventive step standards and strict added matter rules that reward thorough and well-documented original filings. China demands comprehensive experimental support at the time of filing and applies examination standards that require specific attention to claim scope and structure, while offering an increasingly important and enforceable IP environment for life sciences companies. Japan combines meticulous examination standards with a collaborative interview practice and strict procedural deadlines that reward proactive management and experienced local counsel. Across all these systems, the common thread is that the quality of the original application — the completeness of its experimental support, the clarity of its technical disclosure, the precision of its claim drafting, and the strength of its articulated inventive contribution — is the single most important determinant of prosecution success. A well-drafted application that anticipates the requirements of multiple jurisdictions from the outset will navigate each of these systems far more effectively than one that was drafted for a single jurisdiction and adapted for others as an afterthought.

This article is part of our Life Sciences Startup IP Resource Center.